UOC
CRNX

UBS O'Connor’s Crinetics Pharmaceuticals CRNX Stock Holding History

UBS O'Connor’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,978
Closed -$1.15M – 325
2025
Q2 		$1.15M Sell
39,978
-635
-2% -$19.6K 0.03% 198
2025
Q1 		$1.36M Buy
40,613
+12,926
+47% +$483K 0.03% 157
2024
Q4 		$1.42M Buy
27,687
+2,994
+12% +$168K 0.04% 201
2024
Q3 		$1.26M Sell
24,693
-428
-2% -$22.1K 0.03% 250
2024
Q2 		$1.13M Buy
25,121
+19,100
+317% +$882K 0.03% 279
2024
Q1 		$282K Sell
6,021
-4,017
-40% -$157K 0.01% 374
2023
Q4 		$357K Sell
10,038
-16,115
-62% -$494K 0.01% 380
2023
Q3 		$778K Sell
26,153
-30,000
-53% -$618K 0.01% 358
2023
Q2 		$1.01M Buy
56,153
+22,732
+68% +$453K 0.02% 383
2023
Q1 		$537K Sell
33,421
-79,000
-70% -$1.46M 0.01% 460
2022
Q4 		$2.06M Buy
112,421
+21,961
+24% +$387K 0.04% 460
2022
Q3 		$1.78M Buy
90,460
+3,000
+3% +$61.2K 0.02% 658
2022
Q2 		$1.63M Buy
87,460
+22,460
+35% +$448K 0.02% 693
2022
Q1 		$1.43M Buy
+65,000
New +$1.32M 0.02% 642

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

UBS O'Connor's CRNX Position: Q3 2025 in Review

UBS O'Connor sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 39,978 shares — an estimated $1.15M sold.

UBS O'Connor first reported a position in CRNX in Q1 2022 and held it in 14 quarters. The position peaked at $2.06M in Q4 2022. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • UBS O'Connor reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 39,978 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $1.15M.
  • UBS O'Connor first reported a position in Crinetics Pharmaceuticals in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Crinetics Pharmaceuticals position peaked at $2.06M in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.